Multiple Sclerosis and fumarate therapies
Clinical research includes multiple sclerosis with attention to oral disease-modifying therapy and gastrointestinal tolerability in healthy volunteers. The sponsor’s portfolio in this area reflects interest in dimethyl fumarate and related fumarate-based treatments.
- Multiple sclerosis
- Dimethyl fumarate
- Gastrointestinal tolerability
- Oral disease-modifying therapy
These studies focus on treatment-related tolerability and comparative assessment of oral therapies used in neurological disease.
Epilepsy and focal onset seizures
The sponsor is active in refractory partial onset epilepsy, with research centered on focal onset seizures and the clinical performance of levetiracetam formulations. This area links seizure control with extended-release treatment options.
- Refractory partial onset epilepsy
- Focal onset seizures
- Levetiracetam extended release
- Drug-resistant epilepsy
Research in this field addresses seizure frequency reduction and the use of antiepileptic therapy in patients with difficult-to-control epilepsy.
Bioequivalence and comparative bioavailability
A substantial part of the research portfolio involves bioequivalence and comparative bioavailability studies in healthy subjects. These trials evaluate oral formulations intended to match established reference products in systemic exposure.
- Bioequivalence
- Comparative bioavailability
- Healthy subjects
- Oral formulations
Examples include studies of oxazepam orodispersible tablets and other formulation comparisons relevant to central nervous system medicines.
Midazolam formulation comparison
The sponsor also supports research on midazolam in different administration routes, including oromucosal and intramuscular formulations. The focus is on pharmacokinetic comparison in healthy volunteers.
- Midazolam
- Oromucosal solution
- Intramuscular injection
- Pharmacokinetics
This area is relevant to the clinical use of benzodiazepines and formulation selection for rapid therapeutic delivery.
Central nervous system medicines
Across its funded studies, the sponsor shows interest in therapies for the central nervous system, including anxiolytic, antiepileptic, and neurological treatments. The research portfolio spans both established medicines and alternative dosage forms.
- Central nervous system medicines
- Benzodiazepines
- Antiepileptic treatments
- Neurological disorders
The clinical landscape includes formulation-focused work alongside studies in neurology and seizure-related conditions.
